[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565982":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":85,"collaborators":19,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":19,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":38,"whyStopped":19,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Rennes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients","EXPERIMENTAL","All included patients. Bone and blood sampling",[13],"Other: Sampling bone tissue and blood",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Sampling bone tissue and blood","Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Elie COUSIN","University of Rennes","STUDY_CHAIR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Elie COUSIN, Md","CONTACT","299284321","+33","elie.cousin@univ-rennes.fr",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},"marie-laure gervais, phd","marie-laure.gervais@chu-rennes.fr",[36,56,71],{"facility":37,"status":38,"city":39,"state":19,"zip":19,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"CHU Angers","RECRUITING","Angers","France","FR",{"type":43,"coordinates":44},"Point",[45,46],-0.55202,47.47156,{"lat":46,"lon":45},[49,53],{"name":50,"role":28,"phone":51,"phoneExt":30,"email":52},"Isabelle PELLIER, pr","241353637","ispellier@chu-angers.fr",{"name":54,"role":55,"phone":19,"phoneExt":19,"email":19},"Isabelle PELLIER, Pr","PRINCIPAL_INVESTIGATOR",{"facility":57,"status":38,"city":58,"state":19,"zip":19,"country":40,"countryCode":41,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"CHU Brest","Brest",{"type":43,"coordinates":60},[61,62],-4.48628,48.39029,{"lat":62,"lon":61},[65,69],{"name":66,"role":28,"phone":67,"phoneExt":30,"email":68},"Liana CARAUSU, Pr","298223333","liana.carausu@chu-brest.fr",{"name":70,"role":55,"phone":19,"phoneExt":19,"email":19},"Liana CARAUSU, pr",{"facility":72,"status":38,"city":73,"state":19,"zip":19,"country":40,"countryCode":41,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"CHU Rennes","Rennes",{"type":43,"coordinates":75},[76,77],-1.67431,48.11109,{"lat":77,"lon":76},[80,84],{"name":81,"role":28,"phone":82,"phoneExt":30,"email":83},"Virginie GANDEMER, Pr","29928254321","virginie.gandemer@chu-rennes.fr",{"name":81,"role":55,"phone":19,"phoneExt":19,"email":19},{"type":86,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100565982","childhood-b-acute-lymphoblastic-leukaemia-and-role-of-cd9-gene-regulation-in-relapse-100565982",false,"NCT06649253","Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse","REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation","REALL CD9","Inclusion Criteria:\n\n* Under 18 years\n* With established diagnosis of B-ALL\n* Initial diagnosis made in the investigating centre\n* Having received oral and written information about the protocol, or oral only if the patient is unable to read.\n* Having signed a consent form if the patient is capable of giving informed written consent.\n* Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.\n* Beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Isolated extramedullary involvement at inclusion\n* Patient of childbearing age without effective contraception.\n* Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.","ALL","0 Years","17 Years",{"count":99,"type":100},50,"ESTIMATED","INTERVENTIONAL",[103],"NA","B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.",[106],"Leukemia, Lymphoblastic, Acute, Pediatric",[108,109,110],"CD9","miRNA","gene regulation","2025-12-31",{"date":113,"type":114},"2026-01-02","ACTUAL",{"date":116,"type":114},"2025-03-22",{"date":118,"type":100},"2035-04",{"name":5,"class":6},3]